Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GSK4024484 in Healthy Adult Participants
NCT06171113Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK4024484C in Malaria (15 arms), sponsored by GSK. Primary endpoints: Percentage of participants reporting serious adverse events, Percentage of participants reporting SAEs by severity and 2 more. Started Dec 2023; status: completed.
02
Drugs
GSK4024484C
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT06171113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171113.